Phage therapy as a revitalized weapon for treating clinical diseases

Abstract

The rising prevalence of multidrug-resistant (MDR) bacterial infections, coupled with the diminishing efficacy of antibiotics, has reinvigorated interest in bacteriophage (phage) therapy as a promising alternative, leveraging its unique bactericidal mechanisms and precise targeting capabilities. Concurrently, phage display technology has advanced tumor diagnostics and targeted drug delivery through high-throughput peptide screening. This review systematically evaluates the mechanisms, strategies, and clinical progress of phage-based applications in anti-infective and oncological therapies. Clinical evidence highlights its efficacy against respiratory, oral, wound, bloodstream, and urinary tract infections, alongside solid tumors. However, challenges persist, including limited host range, bacterial resistance, immunogenicity, inefficient delivery systems, and regulatory uncertainties. Future efforts should prioritize AI-driven phage optimization, standardized pharmacokinetic assessment, and interdisciplinary collaboration to accelerate clinical translation. Despite current limitations, phage therapy represents a transformative and scalable approach for combating antimicrobial resistance and advancing precision oncology, positioning it as a pivotal tool in addressing global health crises.

Keywords

Phage therapy / multidrug-resistant bacterial infections / tumor therapy / phage display technology / artificial intelligence

References

[1] D'Herelle F.On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917.Res Microbiol2007;158:553-4

[2] Fong K,Wang S.How Broad Is Enough: The Host Range of Bacteriophages and Its Impact on the Agri-Food Sector.Phage (New Rochelle)2021;2:83-91 PMCID:PMC9041489

[3] to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2.Lancet Infect Dis2024;24:e737

[4] Erez Z,Shamir M.Communication between viruses guides lysis-lysogeny decisions.Nature2017;541:488-93 PMCID:PMC5378303

[5] McNair K,Edwards RA.PHACTS, a computational approach to classifying the lifestyle of phages.Bioinformatics2012;28:614-8 PMCID:PMC3289917

[6] Summers WC.Cholera and plague in India: the bacteriophage inquiry of 1927-1936.J Hist Med Allied Sci1993;48:275-301

[7] Jault P,Jennes S.Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.Lancet Infect Dis2019;19:35-45

[8] Dedrick RM,Garlena RA.Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.Nat Med2019;25:730-3 PMCID:PMC6557439

[9] Haddad L, Mendoza JF, Jobin C. Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases.Front Microbiol2022;13:1055427 PMCID:PMC9714271

[10] 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet2022;400:2221-48 PMCID:PMC9763654

[11] Hibstu Z,Akelew Y.Phage therapy: a different approach to fight bacterial infections.Biologics2022;16:173-86 PMCID:PMC9550173

[12] Kaabi SAG.An experimental mouse model for phage therapy of bacterial pathogens causing bacteremia.Microb Pathog2019;137:103770

[13] Kortright KE,Koff JL.Phage therapy: a renewed approach to combat antibiotic-resistant bacteria.Cell Host Microbe2019;25:219-32

[14] Du D,Neuberger A.Multidrug efflux pumps: structure, function and regulation.Nat Rev Microbiol2018;16:523-39

[15] Liu H,Liang Y.Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria.Theranostics2020;10:6310-21 PMCID:PMC7255016

[16] Verma V,Chhibber S.Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae.Biofouling2010;26:729-37

[17] Tan X,Zhang M.Clinical experience of personalized phage therapy against carbapenem-resistant acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease.Front Cell Infect Microbiol2021;11:631585 PMCID:PMC7952606

[18] Li C,Sun Y.A novel method to create efficient phage cocktails via use of phage-resistant bacteria.Appl Environ Microbiol2022;88:e0232321 PMCID:PMC8939320

[19] Uyttebroek S,Onsea J.Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.Lancet Infect Dis2022;22:e208-20

[20] Chen Q,Cai PC.Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics.Pharmaceutics2022;14:1425 PMCID:PMC9318951

[21] De Soir S,Kamarudin NHN.Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections.Microbiol Spectr2024;12:e0321923 PMCID:PMC10783084

[22] Pirnay JP,Steurs G.Bacteriophage Therapy ProvidersBacteriophage DonorsPersonalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.Nat Microbiol2024;9:1434-53

[23] Tagliaferri TL,Horz HP.Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy.Front Cell Infect Microbiol2019;9:22 PMCID:PMC6387922

[24] Stevens RH,Kajsik M.Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis.Front Med (Lausanne)2023;10:1238147 PMCID:PMC10462781

[25] Smug BJ,Drulis-Kawa Z.PhREEPred: Phage resistance emergence prediction web tool to foresee encapsulated bacterial escape from phage cocktail treatment.J Mol Biol2022;434:167670

[26] Cheng M,Li X.Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections.Sci Rep2017;7:10164 PMCID:PMC5579260

[27] Yehl K,Yang AC.Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis.Cell2019;179:459-469.e9 PMCID:PMC6924272

[28] Dedrick RM,Garlena RA,Cornely K.Mycobacteriophage ZoeJ: A broad host-range close relative of mycobacteriophage TM4.Tuberculosis (Edinb)2019;115:14-23 PMCID:PMC6452893

[29] Zajdowicz SLW.Diverse phage-encoded toxins and their role in bacterial ecology. In Hurst CJ, editor. The biological role of a virus. Advances in environmental microbiology, vol 9. Cham: Springer International Publishing; 2022. p. 173-207.

[30] Talbert JN,Nugen SR.Engineering bacteriophage for a pragmatic low-resource setting bacterial diagnostic platform.Bioengineered2016;7:132-6 PMCID:PMC4927197

[31] Schooley RT,Gill JJ.Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection.Antimicrob Agents Chemother2017;61:e00954-17

[32] Nick JA,Gray AL.Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection.Cell2022;185:1860-1874.e12 PMCID:PMC9840467

[33] Lebeaux D,Caudron E.A case of phage therapy against pandrug-resistant achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient.Viruses2021;13:60 PMCID:PMC7824836

[34] Doub JB,Srikumaran U.Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection - a case report.Acta Orthop2022;93:756-9 PMCID:PMC9500534

[35] Li J,He B.Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy.Clin Microbiol Infect2023;29:1601.e1-7

[36] Racenis K,Madelane M.Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant pseudomonas aeruginosa femur osteomyelitis-a case report.Front Med (Lausanne)2022;9:851310 PMCID:PMC9081798

[37] Torabi L, Doudi M, Naghavi NS, Monajemi R. Isolation, characterization, and effectiveness of bacteriophage Pɸ-Bw-Ab against XDR Acinetobacter baumannii isolated from nosocomial burn wound infection.Iran J Basic Med Sci2021;24:1254-63 PMCID:PMC8751751

[38] Teney C,Briot T.PHAGEinLYON Clinic Study GroupPhage therapy in a burn patient colonized with extensively drug-resistant pseudomonas aeruginosa responsible for relapsing ventilator-associated pneumonia and bacteriemia.Viruses2024;16:1080 PMCID:PMC11281479

[39] Stellfox ME,Shields RK.Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia.mBio2024;15:e0339623 PMCID:PMC10936196

[40] Gainey AB,Burch AK.Recurrent ESBL Escherichia coli urosepsis in a pediatric renal transplant patient treated with antibiotics and bacteriophage therapy.Pediatr Infect Dis J2023;42:43-6

[41] Le T,Zhao J.Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections.Antimicrob Agents Chemother2023;67:e0003723 PMCID:PMC10112157

[42] Qvist T,Kragh KN.Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection.Eur Respir J2015;46:1823-6

[43] Yam YK,Go ML.Extreme drug tolerance of mycobacterium abscessus “persisters”.Front Microbiol2020;11:359 PMCID:PMC7064438

[44] Bogovazova GG,Bondarenko VM.[The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection.Zh Mikrobiol Epidemiol Immunobiol1991:5-8

[45] Pozo JL. Biofilm-related disease.Expert Rev Anti Infect Ther2018;16:51-65

[46] Abedon ST,Wozniak DJ.Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth.Pharmaceuticals (Basel)2021;14:1019 PMCID:PMC8541335

[47] Aslam S.Phage therapy in lung transplantation: current status and future possibilities.Clin Infect Dis2023;77:S416-22

[48] Aslam S,Koval C.Early clinical experience of bacteriophage therapy in 3 lung transplant recipients.Am J Transplant2019;19:2631-9 PMCID:PMC6711787

[49] Jaja BNR,Badhiwala JH.Association of pneumonia, wound infection, and sepsis with clinical outcomes after acute traumatic spinal cord injury.J Neurotrauma2019;36:3044-50 PMCID:PMC6791472

[50] Leaper DJ.Traumatic and surgical wounds.BMJ2006;332:532-5 PMCID:PMC1388134

[51] Patel JC,Tepas JJ 3rd.Infectious complications in critically injured children.J Pediatr Surg2000;35:1174-8

[52] Bhartiya SK,Sharma S,Nath G.Biological therapy on infected traumatic wounds: a case-control study.Int J Low Extrem Wounds2024;23:504-12

[53] Garner MR,Schade MA.Antibiotic prophylaxis in open fractures: evidence, evolving issues, and recommendations.J Am Acad Orthop Surg2020;28:309-15

[54] Sudduth JD,Spitler CA.Open fractures: are we still treating the same types of infections?.Surg Infect (Larchmt)2020;21:766-72

[55] Onsea J,Djebara S.Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol.Viruses2019;11:891 PMCID:PMC6832313

[56] Chopra H,Sharun K,Al-Tawfiq JA.Recent advances in the treatment of biofilms induced surgical site infections.Int J Surg2023;109:65-7 PMCID:PMC10389243

[57] Li J,Kirsner R.Pathophysiology of acute wound healing.Clin Dermatol2007;25:9-18 PMCID:PMC2535787

[58] Nadareishvili L,Nakaidze N.Bacteriophage therapy as a potential management option for surgical wound infections.Phage (New Rochelle)2020;1:158-65 PMCID:PMC9041461

[59] Kalan LR.The role of the microbiome in nonhealing diabetic wounds.Ann N Y Acad Sci2019;1435:79-92

[60] Jasim HN,Abdulamir AS.Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study.Iran J Basic Med Sci2018;21:1100-8 PMCID:PMC6251394

[61] Jackson KR,Bae S.Characterizing the landscape and impact of infections following kidney transplantation.Am J Transplant2021;21:198-207 PMCID:PMC12404669

[62] Coussement J,Matignon M.Bacteriuria in Renal Transplantation (BiRT) study groupAntibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial.Clin Microbiol Infect2021;27:398-405

[63] Kim P,Penke TJR.Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.Lancet Infect Dis2024;24:1319-32

[64] Lee D,Kim AR,Yun CH.Enterococcus phage vB_EfaS_HEf13 as an anti-biofilm agent against enterococcus faecalis.J Microbiol2024;62:683-93

[65] Wolfoviz-Zilberman A,Hazan R,Houri-Haddad Y.Phage targeting streptococcus mutans in vitro and in vivo as a caries-preventive modality.Antibiotics (Basel)2021;10:1015 PMCID:PMC8389033

[66] Liu H,Dong A,Yang YW.Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: systematic review, improvements and future challenges.Exploration (Beijing)2024;4:20230092

[67] Petrov G,Richter V.Bacteriophage-mediated cancer gene therapy.Int J Mol Sci2022;23:14245 PMCID:PMC9697857

[68] Zheng DW,Pan P.Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy.Nat Biomed Eng2019;3:717-28

[69] Desmet CJ.Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.Nat Rev Immunol2012;12:479-91

[70] Smith GP.Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.Science1985;228:1315-7

[71] da Fonseca Alves R,Rossi R.Peptide-based biosensing approaches for targeting breast cancer-derived exosomes.Biosens Bioelectron2024;255:116211

[72] Vidal-Calvo EE,Choudhary S.Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.Nat Commun2024;15:7553 PMCID:PMC11364678

[73] Gray BP,Brown KC.From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.Bioconjug Chem2013;24:85-96 PMCID:PMC3561762

[74] Sánchez-Navarro M,Giralt E.Jumping hurdles: peptides able to overcome biological barriers.Acc Chem Res2017;50:1847-54

[75] Wang L,Wang X.Modification of low-energy surfaces using bicyclic peptides discovered by phage display.J Am Chem Soc2023;145:17613-20

[76] Huang W,Boragine DM.Mapping protein-protein interaction interface peptides with Jun-Fos assisted phage display and deep sequencing.ACS Synth Biol2020;9:1882-96 PMCID:PMC7671604

[77] Mimmi S,Quinto I.Phage display: an overview in context to drug discovery.Trends Pharmacol Sci2019;40:87-91

[78] Pung HS,Leow CH,Lai NS.Generation of peptides using phage display technology for cancer diagnosis and molecular imaging.Mol Biol Rep2023;50:4653-64 PMCID:PMC10072011

[79] Hampton JT.Diversification of phage-displayed peptide libraries with noncanonical amino acid mutagenesis and chemical modification.Chem Rev2024;124:6051-77 PMCID:PMC11082904

[80] Chen PC,Zhang HE.Leveraging a phage-encoded noncanonical amino acid: a novel pathway to potent and selective epigenetic reader protein inhibitors.ACS Cent Sci2024;10:782-92 PMCID:PMC11046469

[81] Zhang Y.Evolution of phage display libraries for therapeutic antibody discovery.MAbs2023;15:2213793 PMCID:PMC10210849

[82] Ravn U,Venet S.Deep sequencing of phage display libraries to support antibody discovery.Methods2013;60:99-110

[83] Ledsgaard L,Rimbault C.Advances in antibody phage display technology.Drug Discov Today2022;27:2151-69

[84] Hung LY,Fu CY,Lee GB.Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics.Lab Chip2016;16:2759-74

[85] Wang R,Cao Y,Yang T.M13 phage: a versatile building block for a highly specific analysis platform.Anal Bioanal Chem2023;415:3927-44 PMCID:PMC9982796

[86] Qin Y,Li Y.The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma.Biomater Sci2020;8:5656-65

[87] Sugahara KN,Karmali PP.Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.Science2010;328:1031-5 PMCID:PMC2881692

[88] Yao P,Hu W.Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.Pharmacol Res2024;204:107209

[89] Lawitz EJ,Neff GW.NCT05296733 InvestigatorsEfficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.J Hepatol2024;81:837-46

[90] Li C,Xu Y.Application of phage-displayed peptides in tumor imaging diagnosis and targeting therapy.Int J Pept Res Ther2021;27:587-95 PMCID:PMC7471523

[91] Larimer BM,Smith GP.Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.Mol Imaging Biol2014;16:449-58

[92] Kumar SR.111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.J Nucl Med2008;49:796-803

[93] Dijkgraaf I,McBride WJ.Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.Contrast Media Mol Imaging2013;8:238-45 PMCID:PMC4034708

[94] Liu S,Jiang Y.Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.Bioconjug Chem2007;18:438-46

[95] Vaneycken I,Van Gassen N.Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.FASEB J2011;25:2433-46

[96] Tripathi PP,Banga I,Gandhi S.Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy.Oncotarget2018;9:37252-67 PMCID:PMC6324683

[97] Schmid P,Rugo HS.IMpassion130 Trial InvestigatorsAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med2018;379:2108-21

[98] Powles T,Voog E.Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.N Engl J Med2020;383:1218-30

[99] Garon EB,Arrieta O.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Lancet2014;384:665-73

[100] Fuchs CS,Yong CJ.REGARD Trial InvestigatorsRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2014;383:31-9

[101] Goldstein DA,Ayer T.Necitumumab in metastatic squamous cell lung cancer: establishing a value-based Cost.JAMA Oncol2015;1:1293-300

[102] Paz-Ares L,Ciuleanu TE.INSPIRE investigatorsNecitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.Lancet Oncol2015;16:328-37

[103] Furie R,Houssiau F.Two-year, randomized, controlled trial of belimumab in lupus nephritis.N Engl J Med2020;383:1117-28

[104] Gordon KB,Papp KA.UNCOVER-1 Study GroupUNCOVER-2 Study GroupUNCOVER-3 Study GroupPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.N Engl J Med2016;375:345-56

[105] Nash P,Okada M.SPIRIT-P2 Study GroupIxekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.Lancet2017;389:2317-27

[106] Mease PJ,Gottlieb AB.DISCOVER-2 Study GroupGuselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet2020;395:1126-36

[107] Kreitman RJ,Zinzani PL.Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.Leukemia2018;32:1768-77

[108] Yurkiewicz IR,Ghesquieres H,Kreitman RJ.Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.Leuk Lymphoma2021;62:2812-4 PMCID:PMC8556225

[109] Scully M,Peyvandi F.HERCULES InvestigatorsCaplacizumab treatment for acquired thrombotic thrombocytopenic purpura.N Engl J Med2019;380:335-46

[110] Coppo P,Azoulay E.A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.Blood2021;137:733-42 PMCID:PMC7986049

[111] Chandrakasan S,Baker A.Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.Blood Adv2024;8:2248-58

[112] Verkamp B,Sabulski A,Kieser P.Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism.Blood2024;144:2625-36

[113] Nguyen QD,Marcus DM.RISE and RIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.Ophthalmology2012;119:789-801

[114] Tsai CW.Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration “Animal Rule”.Front Microbiol2015;6:1320 PMCID:PMC4664625

[115] Migone TS,Zhong J.Raxibacumab for the treatment of inhalational anthrax.N Engl J Med2009;361:135-44

[116] Banerji A,Bernstein JA.HELP InvestigatorsEffect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial.JAMA2018;320:2108-21

[117] Pavoni E,Pucci A.Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage.BMC Cancer2004;4:78 PMCID:PMC539249

[118] Shi W,Xie S.A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.Cancer Lett2021;522:184-97

[119] Li D,Liang T.Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours.Nat Commun2023;14:5920 PMCID:PMC10517151

[120] Campbell S,Waramit S,Hajitou A.Selective inhibition of histone deacetylation in melanoma increases targeted gene delivery by a bacteriophage viral vector.Cancers (Basel)2018;10:125 PMCID:PMC5923380

[121] Przystal JM,Pranjol MZI.Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.EMBO Mol Med2019;11:e8492 PMCID:PMC6460351

[122] Wu LP,Su J.Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide.Nat Commun2019;10:4635 PMCID:PMC6789111

[123] Wang T,Gillespie JW.Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.Nanomedicine2014;10:421-30 PMCID:PMC3946195

[124] Xiao L,He H.Development of a novel drug targeting delivery system for cervical cancer therapy.Nanotechnology2019;30:075604

[125] Magaziner SJ.A novel T4- and λ-based receptor binding protein family for bacteriophage therapy host range engineering.Front Microbiol2022;13:1010330 PMCID:PMC9659904

[126] Lin J,Long M.Limitations of phage therapy and corresponding optimization strategies: a review.Molecules2022;27:1857 PMCID:PMC8951143

[127] Zaczek-Moczydłowska MA,Trudgett J.Phage cocktail containing Podoviridae and Myoviridae bacteriophages inhibits the growth of Pectobacterium spp. under in vitro and in vivo conditions.PLoS One2020;15:e0230842 PMCID:PMC7117878

[128] Tetz GV,Zhou H,Tsirigos A.Bacteriophages as potential new mammalian pathogens.Sci Rep2017;7:7043 PMCID:PMC5539208

[129] Rendueles O,Rocha EPC.Competition between lysogenic and sensitive bacteria is determined by the fitness costs of the different emerging phage-resistance strategies.Elife2023;12:e83479 PMCID:PMC10076033

[130] Bernheim A.The pan-immune system of bacteria: antiviral defence as a community resource.Nat Rev Microbiol2020;18:113-9

[131] Oechslin F.Resistance development to bacteriophages occurring during bacteriophage therapy.Viruses2018;10:351 PMCID:PMC6070868

[132] Chan BK,Wertz JE,Narayan D.Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa.Sci Rep2016;6:26717 PMCID:PMC4880932

[133] Kortright KE,Evans BR.Arms race and fluctuating selection dynamics in Pseudomonas aeruginosa bacteria coevolving with phage OMKO1.J Evol Biol2022;35:1475-87

[134] Baqer AA,Mohd-Assaad N,Md Nor NS.In vitro activity, stability and molecular characterization of eight potent bacteriophages infecting carbapenem-resistant klebsiella pneumoniae.Viruses2022;15:117 PMCID:PMC9860934

[135] Fister S,Witte AK,Wagner M.Influence of environmental factors on phage-bacteria interaction and on the efficacy and infectivity of phage P100.Front Microbiol2016;7:1152 PMCID:PMC4964841

[136] Matsuda T,Hilbert DW.Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model.Surgery2005;137:639-46

[137] Topka-Bielecka G,Necel A.Bacteriophage-derived depolymerases against bacterial biofilm.Antibiotics (Basel)2021;10:175 PMCID:PMC7916357

[138] Johansson ME,Pelaseyed T.Composition and functional role of the mucus layers in the intestine.Cell Mol Life Sci2011;68:3635-41 PMCID:PMC11114784

[139] Kim SG,Yun S.Synergistic phage-surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo.Int J Antimicrob Agents2020;56:105997

[140] Porter SB,Kisiela D,Sokurenko EV.Bacteriophage cocktail and microcin-producing probiotic Escherichia coli protect mice against gut colonization with multidrug-resistant Escherichia coli sequence type 131.Front Microbiol2022;13:887799 PMCID:PMC9082999

[141] Gelman D,Alkalay-Oren S.Clinical phage microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy.Lancet Microbe2021;2:e555-63

[142] Kaneko T,Tsuneda S.Tailoring effective phage cocktails for long-term lysis of escherichia coli based on physiological properties of constituent phages.Phage (New Rochelle)2023;4:128-35 PMCID:PMC10574527

[143] Vázquez R,Domingo-Calap P.Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: a perspective from Spain.Microorganisms2022;10:717 PMCID:PMC9025261

[144] Nagel T,Muthoni M,Nakavuma JL.Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world.Curr Opin Virol2022;53:101208 PMCID:PMC8846552

[145] Le S,Wang J.Bacteriophage protein Dap1 regulates evasion of antiphage immunity and Pseudomonas aeruginosa virulence impacting phage therapy in mice.Nat Microbiol2024;9:1828-41

[146] Kassa T.Bacteriophages against pathogenic bacteria and possibilities for future application in Africa.Infect Drug Resist2021;14:17-31 PMCID:PMC7797301

[147] Yerushalmy O,Alkalay-Oren S.Towards standardization of phage susceptibility testing: the Israeli phage therapy center “clinical phage microbiology”-a pipeline proposal.Clin Infect Dis2023;77:S337-51

[148] Khatami A,Warner MS.Phage Australia Clinical NetworkStandardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial.BMJ Open2022;12:e065401 PMCID:PMC9743374